International Journal of Cancer Management

Published by: Kowsar

Co-Administration of Anti-Angiogenic Peptide and DNA Vaccine in Cervical Cancer Tumor Model

Parisa Saadat 1 , Hoorieh Soleimanjahi 1 , * , Seyed Mohsen Asghari 2 , Maryam Fazeli 1 , Hadi Razavinikoo 1 and Hesam Karimi 1
Authors Information
1 Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran
2 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, IR Iran
Article information
  • International Journal of Cancer Management: March 2017, 10 (3); e4723
  • Published Online: March 25, 2017
  • Article Type: Research Article
  • Received: January 9, 2016
  • Revised: June 1, 2016
  • Accepted: March 1, 2017
  • DOI: 10.5812/ijcm.4723

To Cite: Saadat P, Soleimanjahi H, Asghari S M, Fazeli M, Razavinikoo H, et al. Co-Administration of Anti-Angiogenic Peptide and DNA Vaccine in Cervical Cancer Tumor Model, Int J Cancer Manag. 2017 ; 10(3):e4723. doi: 10.5812/ijcm.4723.

Abstract
Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-917[DOI][PubMed]
  • 2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74-108[PubMed]
  • 3. Chuang CM, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine. 2009; 27(5): 684-9[DOI][PubMed]
  • 4. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009; 27(3): 431-40[DOI][PubMed]
  • 5. Steinberg T, Ohlschlager P, Sehr P, Osen W, Gissmann L. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Vaccine. 2005; 23(9): 1149-57[DOI][PubMed]
  • 6. Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J Virol. 2003; 77(8): 4928-37[PubMed]
  • 7. Samorski R, Gissmann L, Osen W. Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol Lett. 2006; 107(1): 41-9[DOI][PubMed]
  • 8. Riemer AB, Keskin DB, Zhang G, Handley M, Anderson KS, Brusic V, et al. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem. 2010; 285(38): 29608-22[DOI][PubMed]
  • 9. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res. 2006; 312(5): 594-607[DOI][PubMed]
  • 10. Huang X, Wong MK, Zhao Q, Zhu Z, Wang KZ, Huang N, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res. 2001; 61(2): 478-81[PubMed]
  • 11. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2): 277-85[PubMed]
  • 12. Chamani R, Asghari SM, Alizadeh AM, Eskandari S, Mansouri K, Khodarahmi R, et al. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights. Vascul Pharmacol. 2015; 72: 73-82[DOI][PubMed]
  • 13. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996; 56(1): 21-6[PubMed]
  • 14. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, et al. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res. 1999; 59(24): 6251-6[PubMed]
  • 15. Meshkat Z, Soleimanjahi H, Mahmoudi M, Hassan ZM, Mirshahabi H, Meshkat M, et al. CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate. Iran J Immunol. 2008; 5(2): 82-91[PubMed]
  • 16. Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, Ghaemi A, Fazeli M. HSP70 modified response against HPV based tumor. Eur Rev Med Pharmacol Sci. 2013; 17(2): 228-34[PubMed]
  • 17. Mirshahabi H, Soleimanjahi H, Pourpak Z, Meshkat Z, Hassan ZM. Production of human papilloma virus type 16 e6 oncoprotein as a recombinant protein in eukaryotic cells. Iran J Cancer Prev. 2012; 5(1): 16-20[PubMed]
  • 18. Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008; 26 Suppl 10-61[DOI][PubMed]
  • 19. Fazeli M, Soleimanjahi H, Dadashzadeh S. Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model. Iran J Cancer Prev. 2015; 8(1): 18-23[PubMed]
  • 20. Diniz MO, Lasaro MO, Ertl HC, Ferreira LC. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol. 2010; 17(10): 1576-83[DOI][PubMed]
  • 21. Hattis D, Goble R, Chu M. Age-related differences in susceptibility to carcinogenesis. II. Approaches for application and uncertainty analyses for individual genetically acting carcinogens. Environ Health Perspect. 2005; 113(4): 509-16[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments